Either they entered a quite period or there is nothing going on. 3 years of empty promises and the only thing to show for it is a drop in share price.
Is this dead wood?
I will give this laggard 30 more days until I bail out. Until then, I expect about 2 to 3 more updates without any substantive information or contracts and revenue generating news. Frustrating, very frustrating! And I am frustrated because of all the updates that create hype and then no deal(s) leads to such disappointment as is the case now. Think I am wrong? Just look at $.135/share!
Received an award from the surgeon general a year of so ago, received patent(s), orphan drug status, top scientists validating the drug, fast-track approval, etc. and now we find out it simply doesn't work... And as a matter of fact, the recurrence rate was higher for those on the drug? Something doesn't seem right! Did everyone get fleeced???
They need to start the trial in conjunction with the Herceptin asap. No wonder Roche or others kept their distance. I think something is going to shake out by next week as they unblind the study. Something really seems like it went wrong somewhere.
All these updates have led to nothing specific in the way of revenue generation... Anyone else concerned? How about you jibjob??? You have been quite. Pumped heavy now disappeared. I suspect you still read this board and are reading to sow your face if in fact something does happen. So far you have been dead wrong. Keep in mind, I am still long with this stock but the clock is ticking on when I will or will not bail.
Like a lot of others I go slammed today. And we could break $.20 in a week or so as margin calls are settled. I just have a hard time believing that the drug not only didn't work, patients ended up being worse off than those who were not on it. Last week I said that the shorts were firmly in control and I was right, even in the face of getting based for saying it. I should have went with my gut instinct, or should I say my other gut instinct.
Believe it or not, I added 40,000 shares to my position today and if we see south of $.25, I will add another 50,000 shares. This will dollar cost me down to about $.68. And there is as chance we may never see $.68 but who knows...
I said it the other day that I am long GALE but got bashed when I said that the shorts are in complete control. Blockbusting news is the only thing that will cure this diseased stock. Bashing articles support these shorts and it is an endemic problem in the market in general.
Hope is not a strategy, solid news is.
I think this is setting up for a settlement m friends... Kevi drops the appeal and both sides agree to licenses and they live happily ever after. Let's not forget, Kevi is and attorney in his own right so this could get interesting. Thank God they still have clients and a revenue stream...
I don't think any pivotal decisions will be made today unless the judge throws it out, which is likely.
Large volume and a very strong morning but there was no follow-thru buying, no big money support. Just pure manipulation...
But guess what, their time will come and when it does, a lot of these #$%$-balls will loose everything.
Then around 2:30 it starts heading higher. Lunch time doldrums so don't worry, time to buy more under $2.40. we may close around $2.60 today.
The billing person at my family doctor swiped my FSA Mater Card yesterday and within 5 seconds the transaction went thru and I signed her smart phone with my finger. The confirmation of the transaction took less than 15 secs total. I am sold, and they love the back end reporting...
zerosum2013 is really jibjob. They sound (type) too much alike. Caught!
We need sales, end of story!
An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.
In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.
Analysis? I am waiting for the company statement that says we are reviewing the test and will analyze the review of the test.